#China #Shenzhen #CGM #AGP #DTx

Transforming Diabetes Management: Key Takeaways from the 2026 AGP & DTx Summit

In May 2026, the 4th AGP & DTx Summit was successfully held in Shenzhen, China. The summit's theme, "Beyond Glucose," underscored the significant advancements in diabetes care driven by digital therapies and Continuous Glucose Monitoring (CGM) systems. As the co-hosting organization, SIBIONICS brought together international health professionals, researchers, educators, and patient representatives to share knowledge on the clinical value of CGM data.

One of the predominant messages from the summit was that CGM should not merely be seen as a monitoring tool; rather, its true potential lies in translating glucose data into meaningful clinical insights. This transformation enables healthcare providers to make informed treatment decisions and foster behavioral changes among patients.

Professor Andrej Janež presented a progress report from the International Consortium for Research and Development, detailing achievements over the past two years. The research fund has supported 20 investigator-initiated trials across 14 nations, focusing on various facets of CGM and the Continuous Ketone Monitoring (CKM) system. Areas of investigation included accuracy in specific populations, dietary patterns, glycemic responses, AI-enabled platforms, and clinical monitoring applications.

Further emphasizing the importance of digital therapy, Professor Sofianos Andrikopoulos asserted that these therapies can integrate program-controlled interventions, lifestyle guidance, medication support, and comprehensive care models. Notably, the evidence presented showed that AGP & DTx therapies correlated with an average HbA1c reduction of 0.54 percentage points, validating their efficacy in structured diabetes management.

From a clinical phenotype perspective, Professor Wei Qiang illustrated how integrating routine admission parameters with CGM data and the Ambulatory Glucose Profile (AGP) can aid in identifying metabolic phenotypes and treatment responses among hospitalized Type 2 diabetes patients, paving the way for more personalized and targeted care.

Delving into the intersection of technology and patient management, Professor Shannon Lin cautioned that CGM alone may reach a plateau in effectiveness. Consequently, data-driven management is paramount, reflecting a strong interest from both physicians and patients in merging CGM with AI to develop predictive models and tailored recommendations.

Additionally, Professor Xiao Luo highlighted findings that showed CGM and CKM could effectively map glucose and ketone changes throughout fasting and feeding cycles, enhancing the feasibility of metabolic interventions.

A profound moment was presented by Tom Vesely, a patient living with Type 1 diabetes for nearly four decades. He reminded attendees that while CGM aids in visualizing daily glucose fluctuations, the ultimate aim extends beyond merely achieving better Time in Range; it is about enriching “Time in Happiness.”

Overall, the discussions at the AGP & DTx Summit signal a pivotal evolution in diabetes care, steering the focus from mere monitoring toward holistic change through informed, technology-driven strategies. The collaboration of multi-disciplinary experts signifies a promising horizon for improving the lives of those affected by diabetes through comprehensive engagement and innovative solutions.